Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study.
Takashi NakanoKozo KuribayashiMasashi KondoMasahiro MoriseYuji TadaKatsuya HiranoMorihiko HayashiMisa TanakaMasataka HirabayashiPublished in: Asia-Pacific journal of clinical oncology (2020)
Bevacizumab plus cisplatin/pemetrexed then bevacizumab was well tolerated in Japanese patients with MPM.